Meta-analytic Phase II clinical trial
A meta-analytic Phase II clinical trial integrates individual or aggregate data from multiple single-arm or small Phase II studies into a unified meta-analytic framework. Rather than relying on a single underpowered trial to screen for activity, this design pools evidence across comparable cohorts to obtain a more reliable estimate of treatment response, enabling better-informed go/no-go decisions before committing to a large Phase III randomized trial.
Izvorni zapis
Citati kopirani doslovno iz izvornog zapisa metode. Ne impliciraju nikakvu provjeru na razini tvrdnje.
- Warmuth, M., & Hinzmann, B. (2013). Phase II trials in oncology: From the statistical design of trials to the meta-analysis of the results. Onkologie, 36(9), 555–564. · URL
- Sutton, A. J., Cooper, N. J., Jones, D. R., Lambert, P. C., Thompson, J. R., & Abrams, K. R. (2007). Evidence-based sample size calculations based upon updated meta-analysis. Statistics in Medicine, 26(12), 2479–2500. · DOI 10.1002/sim.2704
Uređene tvrdnje
Tvrdnje pohranjene u knjigu dokaza, svaka s vlastitom procjenom.
Ovaj prikaz ne izmišlja procjenu tvrdnje kada knjiga dokaza nema nijednu.
Povezane metode
Generirano iz grafa metode i prikazano kao strojno predložene relacije — ne implicira se nikakva tvrdnja dokaza.